Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ONKT101

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Avectas, ONK Therap

Drug class:

CD19 inhibitor, TRAIL R2 agonist

Related drugs:

‹

universal chimeric antigen receptor-modified AT19 cells (0)

blinatumomab (52)

tafasitamab-cxix (3)

BTN2A1/3A1-Fc-CD19scFv (0)

CAR-NK-CD19 cells (0)

CB CAR-NK019 (0)

CD19.t-haNK (0)

Imtox19/Imtox22 (0)

inebilizumab-cdon (0)

anti CD19/CD22 CAR NK cells (0)

autologous TRAC locus-inserted CD19-STAR-T (0)

dualCAR-NK19/70 (0)

universal chimeric antigen receptor-modified AT19 cells (0)

›